CJC-1295 comparisons require the exact peptide structure and any albumin-reactive modification. Primary preclinical work examined a specifically modified growth-hormone-releasing-factor analog designed for albumin association. A product labeled without DAC cannot be assumed to be that same structure with identical properties, and a commercial label alone does not establish kinetics.
- Resolve the sequence and linker chemistry before comparing labels.
- The primary CJC-1295 study tested a defined albumin-reactive analog.
- Model-system persistence is not a universal half-life for all related listings.
- No human half-life, dosing or administration guidance is provided here.
What does DAC terminology attempt to distinguish?
DAC is commonly used to refer to the drug-affinity-complex feature associated with albumin-reactive modification in this family of descriptions. The scientifically useful distinction is the actual structure: the peptide sequence, substitutions and chemical group capable of association with albumin. The abbreviation alone does not fully specify those features.
Some catalog descriptions use CJC-1295 without DAC for related GHRH or GRF analogs. Such terminology should not replace sequence documentation. Do not assume that a material is the precise peptide portion of the published CJC-1295 structure, or that removing an indicated linker leaves every other structural feature unchanged.
What did the primary preclinical study examine?
Jetté and colleagues described a modified human GRF(1-29) analog with an albumin-reactive maleimide-containing feature. The work included cultured rat pituitary measurements and rat experiments examining albumin association and persistence. It supports interpretation of the defined molecule and models used in that paper, rather than all preparations bearing a similar commercial name.
This article excludes human clinical-trial results and does not provide dosing or administration details. Its purpose is to explain the relationship between chemical identity and interpretation. A model-specific persistence observation cannot be converted into a standard half-life for an unspecified no-DAC preparation.
Structure-first comparison checklist
| Question | Albumin-reactive material | A listing described as without DAC |
|---|---|---|
| What is the exact sequence? | Confirm all stated substitutions and terminal features | Confirm independently rather than infer from the label |
| Is a reactive linker present? | Require explicit structural documentation | Require the stated chemical form |
| Which paper matches the material? | A study of the same defined structure | A study of the matching structure, if available |
| What does expected mass represent? | The specified molecule or assigned species | The independently specified molecule |
| What supports a kinetic claim? | Applicable experimental measurements | Not a borrowed claim from a different analog |
Why albumin association affects the analytical question
A reactive peptide and its albumin-associated species are different analytical objects. Evidence about the starting material is not the same as evidence about an associated species in a biological model. A study may use different techniques to examine molecular identity, association and persistence, and each result should be connected to its purpose.
A COA for a peptide powder can provide identity and purity information about that sample. It does not by itself demonstrate albumin association in a model or determine a biological half-life. Those attributes require experiments designed to measure them. The distinction prevents an analytical label from becoming an unsupported kinetic claim.
How to read GH-axis model findings
Cultured pituitary measurements represent a defined model-system endpoint. They do not establish a general outcome across organisms, nor do they authenticate a different supplier material. When a paper discusses a releasing-factor analog, preserve the exact material name and structure alongside the model and endpoint.
Receptor-related terminology, release measurements and persistence are separate evidence categories. A result in one category should not be substituted for another. This review does not present human effects or outcomes, and it does not compare preparations through assumed clinical potency.
Questions for a material’s documentation
- Does the report specify the sequence and terminal modifications unambiguously?
- Is the presence or absence of albumin-reactive chemistry stated?
- Does the expected mass correspond to that structure?
- Are the observed ion assignments and chromatographic results tied to the same lot?
- Which kinetic statements, if any, are supported by matching experimental evidence?
If a label is ambiguous, request clarification before interpreting a comparison. A missing structural detail is not evidence that two preparations are equivalent. For the same reason, do not calculate an expected mass or select a literature half-life solely from a short marketing name. The identity record is the starting point for both analytics and a responsible literature summary.
Connect the literature to the actual lot
A published study describes the material and model used by its authors. It does not authenticate a current supplier lot or establish that a catalog item has the same sequence, chemical form or analytical attributes. Keep those two evidence trails separate.
Start with the label and report for the material under evaluation. Match the compound name and lot identifier, then inspect the methods, dates, chromatogram and identity evidence actually provided. Do not infer unreported tests from a high purity percentage. View lot-level testing reports and use the COA verification guide to record any unanswered questions. Documentation varies by compound and lot; a library entry is a starting point for checking the underlying report.
Frequently asked questions
Is without DAC a complete chemical specification?
No. The exact sequence, substitutions and terminal chemistry must still be documented.
Does a powder COA establish albumin association or biological persistence?
No. Those are separate experimental attributes beyond a typical identity and chromatographic purity record.
Can a published CJC-1295 half-life be assigned to every related listing?
No. Kinetic measurements apply to the tested structure and model; they cannot be transferred from the label alone.
Continue with the documentation guides
Sources and scope
Selected primary research and analytical references. These references support the specific model or measurement discussed; they do not certify SRL materials or establish human outcomes.
Prepared by Stealth Research Labs. Source check: October 1, 2026.
Strictly for laboratory research use only. Not for human or animal consumption. No dosing, administration, or protocol guidance.
[…] CJC-1295 terminology and identity […]
[…] CJC-1295 terminology and identity […]
[…] the DAC terminology guide when resolving the CJC designation. Keep the supplier’s declared structure, the report sample and […]
[…] a deeper identity review, read CJC-1295 with DAC versus without DAC. Do not transfer exposure durations from a DAC study to a no-DAC listing or turn a published […]